<DOC>
	<DOCNO>NCT02736799</DOCNO>
	<brief_summary>The Vibrant capsule novel vibrate device treatment gastrointestinal disorder . The effect different vibration motor function gastrointestinal tract unclear . The study focus stomach healthy volunteer . The study compare effect Vibrant capsule treatment Sham capsule treatment gastric empty gastric motility healthy volunteer .</brief_summary>
	<brief_title>Effect Vibrant Capsule Gastric Emptying Antropyloroduodenal Motility Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Gastroparesis</mesh_term>
	<criteria>1 . Able provide write informed consent prior study procedure , willing able comply study procedures 2 . No medical problem chronic disease , specifically , type 2 diabetes mellitus 3 . Body mass index 1835 kg/m2 4 . Female subject must negative urine pregnancy test must lactate prior receive study medication radiation exposure . For female able bear child , hormonal ( i.e. , oral , implantable , injectable ) singlebarrier method , doublebarrier method birth control must use throughout study . Female subject unable bear child must document medical record [ i.e. , tubal ligation , hysterectomy , postmenopausal ( define minimum one year since last menstrual period ) ] . 1 . Unable unwilling provide inform consent comply study procedures 2 . Diagnosis gastrointestinal disease 3 . Structural metabolic disease affect gastrointestinal system 4 . Unable avoid follow overthecounter medication 48 hour prior baseline period throughout study : 1 . Medications alter gastrointestinal transit include laxative , magnesium aluminum contain antacid , prokinetics , erythromycin 2 . Analgesic drug include Nonsteroidal AntiInflammatory Drugs COX2 inhibitor NOTE : stable dos thyroid replacement , estrogen replacement , lowdose aspirin cardioprotection , birth control ( adequate backup contraception druginteractions birth control conduct ) permissible . 5 . History recent surgery ( within 60 day screen ) 6 . Acute chronic illness history illness , opinion investigator , could pose threat harm subject obscure interpretation laboratory test result interpretation study data , frequent angina , Class III IV congestive heart failure , moderate impairment renal hepatic function , poorly control diabetes , etc . 7 . Any clinically significant abnormality physical examination laboratory abnormality identify medical record , determine investigator 8 . Acute gastrointestinal illness within 48 hour initiation baseline period 9 . Females pregnant breastfeed 10 . History excessive alcohol use substance abuse 11 . Participation investigational study within 30 day prior dose present study 12 . Any reason , opinion investigator , would confound proper interpretation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>